CLRB

Cellectar Biosciences Inc. is a clinical biopharmaceutical company based in Florham Park, New Jersey, specializing in the development of innovative cancer therapies via its proprietary phospholipid drug conjugate (PDC) platform. This technology allows for the selective delivery of therapeutics to tumor cells, optimizing therapeutic efficacy while reducing adverse effects. With a promising pipeline of drug candidates targeting significant unmet needs in oncology, Cellectar is strategically positioned to enhance cancer treatment and improve patient outcomes, presenting a compelling opportunity for institutional investors focused on breakthrough biopharmaceutical innovations.